First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctdna analysis from dose escalation
Year: 2025
Type: conference-abstract
Source: Blood
Institutions: City Of Hope National Medical Center, University of Washington, Fred Hutch Cancer Center, University of California, San Francisco, University of Copenhagen, Rigshospitalet, Vall d'Hebron Hospital Universitari, University of Manchester, The Christie NHS Foundation Trust, University of Kansas Medical Center, Nebraska Medical Center, University of Nebraska Medical Center, Pfizer (United States), University of Verona
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417012782